Advertisement
Advertisement
U.S. Markets close in 1 hr 15 mins
Advertisement
Advertisement
Advertisement
Advertisement

SHANG.FOS.PHARM.GR.H YC 1 (08HH.DU)

Dusseldorf - Dusseldorf Delayed Price. Currency in EUR
2.8660+0.0010 (+0.03%)
As of 06:30PM CET. Market open.
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.8650
Open2.8980
Bid2.8680 x N/A
Ask3.0040 x N/A
Day's Range2.8660 - 2.9090
52 Week Range2.8660 - 2.9090
Volume700
Avg. VolumeN/A
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Zacks

    Syneos Health (SYNH) to Launch Serplulimab With New Pact

    Syneos Health's (SYNH) new partnership will develop an advanced commercialization model to serve healthcare professionals and patients in the best possible way in today's changing environment.

  • GlobeNewswire

    Syneos Health Announces Partnership with Fosun Pharma USA to Launch Serplulimab

    Relationship Will Leverage Syneos One Expertise, Accessing Clinical and Commercial SolutionsMORRISVILLE, N.C., Jan. 11, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced a strategic partnership with Fosun Pharma USA Inc. (“Fosun Pharma USA“), the US-based subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”; stock code: 600196. SH, 02196. HK). As part of the partnership, Syneos Healt

  • PR Newswire

    Fosun Pharma and Henlius Entered into an Exclusive License Agreement for Serplulimab in the US

    Fosun Pharma (600196.SH, 02196.HK) has recently entered into an exclusive license agreement with Shanghai Henlius Biotech, Inc. (2696.HK) for the commercialisation of Henlius independently developed anti-PD-1 monoclonal antibody (mAb) serplulimab in the United States (US). This marks an important milestone for Fosun Pharma's development in the US.

Advertisement
Advertisement